EUVIMEDEUVIMED entdecken
Crossref

Ivosidenib in the treatment of patients with IDH1 mutated cholangiocarcinoma

Agnieszka Chmielewska, Tomasz Kubiatowski

Oncology in Clinical Practice · 21.08.2024 · 20 (4) · 286-290

DOI: 10.5603/ocp.97707 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology in Clinical Practice, online erschienen am 21.08.2024. Verfasst von Agnieszka Chmielewska und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Chmielewska, A., & Kubiatowski, T. (2024). Ivosidenib in the treatment of patients with IDH1 mutated cholangiocarcinoma. Oncology in Clinical Practice, 20(4), 286-290. https://doi.org/10.5603/ocp.97707

Vancouver

Chmielewska A, Kubiatowski T. Ivosidenib in the treatment of patients with IDH1 mutated cholangiocarcinoma. Oncology in Clinical Practice. 2024;20(4):286-290. doi:10.5603/ocp.97707

BibTeX
@article{Chmielewska2024,
  author = {Chmielewska, Agnieszka and Kubiatowski, Tomasz},
  title = {Ivosidenib in the treatment of patients with IDH1 mutated cholangiocarcinoma},
  journal = {Oncology in Clinical Practice},
  year = {2024},
  volume = {20},
  number = {4},
  pages = {286--290},
  doi = {10.5603/ocp.97707}
}
Kostenlos starten →